

2016 FULL YEAR RESULTS INVESTOR PRESENTATION

22 AUGUST 2016



FULL YEAR RESULTS 2016

nib



Disclaimer

The material in this presentation is a summary of the results of nib holdings limited (nib) for the 12 months ended 30 June 2016 and an update on nib's activities and is current at the date of preparation, 22 August 2016. Further details are provided in nib's full year accounts and results announcement released on 22 August 2016.

This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in nib in any jurisdiction. This presentation contains general information only and does not take into account the investment objectives, financial situation and particular needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their objectives, financial situation and needs before taking any action.

The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. Nothing in this presentation constitutes an offer or invitation to issue or sell, or a recommendation to subscribe for or acquire securities in any jurisdiction where it is unlawful to do so.

An investment in nib securities is subject to investment and other known and unknown risks, some of which are beyond the control of nib. nib does not guarantee any particular rate of return or the performance of nib securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, reliability, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness, fairness, accuracy, reliability, completeness or correctness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("forward-looking statements"). Whilst the forward-looking statements are based on current views, expectations and beliefs as at the date they are expressed, such forward-looking statements are by their nature subject to significant uncertainties and contingencies and are based on a number of estimates and assumptions that are subject to change (and in many cases are outside the control of nib and its Directors) which may cause the actual results or performance of nib to be materially different from any future results or performance expressed or implied by such forward-looking statements. Accordingly, there can be no assurance or guarantee that these forward-looking statements will be realised.

This presentation provides information in summary form only and is not intended to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.

The financial information disclosed has been prepared on a statutory basis, which is consistent with the financial information provided in nib's Listing Prospectus. Due care and consideration should be undertaken when considering and analysing nib's financial performance. All references to dollars are to Australian Dollars unless otherwise stated.

To the maximum extent permitted by law, neither nib nor its related corporations, Directors, officers employees or agents, nor any other person, accepts any liability (direct, indirect or consequential) including, without limitation, any liability arising from fault or negligence, for any loss whatsoever arising from the use of this presentation or its contents or otherwise arising in connection with it (whether foreseeable or not).

This presentation should be read in conjunction with other publicly available material. Further information including historical results and a description of the activities of nib is available on our website: www.nib.com.au/shareholders

As referenced in this presentation, if there is a change percentage increase or (decrease) between FY15 and FY16 the change shown is the difference between those two percentages.

Any discrepancies between totals and sums of components in this publication are due to rounding.

All figures quoted are in Australian dollars unless otherwise stated.

A group of people are running on a beach towards the ocean at sunset. The scene is captured in a warm, golden light, with the sun low on the horizon. The people are silhouetted against the bright sky and water, and they are splashing water as they run. The overall mood is energetic and joyful.

Mark Fitzgibbon

CEO & MANAGING DIRECTOR

FULL YEAR RESULTS 2016

nib



Snapshot

Underlying business performance



Group revenue¹ grew by \$233.8m (▲14.3%) to \$1.9b with underlying operating profit² (UOP) up by \$44.0m (▲49.9%) to \$132.0m³ (statutory operating profit of \$120.8m ▲47.9%). All business segments grew and improved UOP.



arhi with organic growth of 19,501 policies grew 3.8% in a very competitive market and with a higher gross margin increased UOP by \$22.6m.



Businesses other than arhi increased UOP by 132% to \$37.5m and accounted for 28.4% of Group UOP (compared to 18.3% in FY15). Within this, World Nomads Group made inaugural contribution of \$9.7m. nib NZ doubled UOP to \$17.3m.



arhi net promoter score of 17.7 compared with 20.7 in FY15. Some media coverage hostile to the industry was unhelpful.



Ongoing diversification (World Nomads Group), innovation (Qantas Assure) and disruption (Whitecoat).

¹ Excludes non-recurring profit from sale of Newcastle office building.

² UOP is comprised of underwriting result, other income and expenses including non-underwriting businesses. It excludes amortisation of acquired intangibles, one-off transactions, M&A costs, finance costs, net investment income and income tax.

³ nib's statutory operating profit includes \$11.2m in amortisation of acquired intangibles and one-off transactions and M&A costs.




Snapshot

Group profitability



- Net investment income of \$16.9m was lower than FY15 (\$31.4m). Previous year included one-off profit on sale of shares in PSG (\$5.4m).
- Net Profit After Tax of \$91.8m (▲22.0%), EPS of 21.2cps (FY15: 17.3cps).
- Final ordinary dividend of 9.0cps (▲50.0%), fully franked (14.75cps for full year ▲28.3%). TSR of 30.0% versus (0.5)% for ASX200.



Source: Bloomberg




arhi gross margin improvement a key driver



- Claims inflation experience and trajectory favourable.
- Lower hospital and ancillary utilisation growth the primary explanation.
- nib experience accentuated by tactical product changes in FY15.

Annual drawing rate inflation nib versus industry (Rolling 12 months)




Gross margin nib versus industry (Rolling 12 months)



¹ Includes risk equalisation
Source: nib/APRA



Strong operating cash flow correlating with UOP



¹FY12 & FY13 normalised for pre-payments of premiums in May/June 2012 associated with introduction of income testing of Government Rebate. FY12 normalised for pre-payments of premiums in May/June 2012 associated with introduction of income testing of Government Rebate is lower than FY11 mainly due to \$7m decrease in distributions received from investment trusts and \$10m increase in income.



Whitecoat

Tackling information asymmetries and improving market efficiency



- Whitecoat enables consumers to search, find and book a healthcare provider as well as review their experience. Currently hosts more than 210,000 health care and ancillary providers and over 250,000 customer reviews.
- Rapidly expanding to include GPs and medical specialists.
- Recent announcement to form JV with BUPA and HBF will significantly expand reach and consumer engagement (~6 million people). Open invitation extended to other insurers and healthcare payers to participate.
- Allows insurer/payer to host "customer only" portal for deeper engagement and insurer/payer specific information such as preferred clinical providers and "no gap" arrangements.
- When fully developed will also include accredited clinical performance information including self-reported patient outcomes.
- Additional near term opportunities to automate patient/provider transactions such as payments and prescriptions.



A person is running on a paved path that leads towards a body of water at sunset. The sun is low on the horizon, creating a warm, golden glow across the sky and reflecting on the water. The person is seen from behind, their silhouette highlighted by the bright light. The sky is filled with soft, wispy clouds.

Michelle McPherson

CHIEF FINANCIAL OFFICER & DEPUTY CEO

nib



FY16 Financial Summary

Outperformance across key performance areas



	FY16	FY15	Change
Total Group revenue (\$m)	1,873.1 ¹	1,639.3	14.3%
UOP (\$m)	132.0	88.0	49.9%
Amortisation of acquired intangibles, one-off transactions and M&A costs (\$m)	(11.2)	(6.4)	75.8%
Statutory operating profit (\$m)	120.8	81.7	47.9%
Net investment income ² (\$m)	16.9	31.4	(46.2)%
NPAT (\$m)	91.8	75.3	22.0%
Underlying EPS (cps)	22.9	18.3	25.1%
Statutory EPS (cps)	21.2	17.3	22.5%
Dividend (cps)	14.75	11.5	28.3%
ROE (%)	25.8	23.1	2.7%

¹ Excludes non-recurring profit from sale of Newcastle office building

² Net investment income in FY15 benefited \$5.4m from of sale of shareholding in Pacific Smiles Group




Total Group Revenue

Continued strong revenue growth



Total revenue by segment



Total Group revenue of \$1.9b¹ (▲ 14.3%) due to:

- arhi premium revenue of \$1.6b (▲ 9.7%), accounting for 83.7% of total group revenue.
- International (inbound) health insurance (iihi) premium revenue of \$76.8m (▲ 39.7%).
- nib New Zealand premium revenue of \$173.6m (▲ 15.4%), includes acquisition of OnePath (NZ) health insurance (7 month result).
- First-time inclusion of World Nomads Group (WNG) with operating revenue of \$50.0m (11 month result).

¹ Excludes non-recurring profit from sale of Newcastle office building
Refer Slide 30 for breakdown of Other income




Group UOP

Earnings improvement across key business segments



UOP by segment



Group UOP of \$132.0m (▲49.9%) due to:

- Significant improvement in arhi UOP up 31.4% to \$94.5m with improved claims experience a key driver. arhi continues to be core contributor to Group UOP (71.6% of Group).
- Growth in adjacent businesses accounted for 28.4% of Group UOP (FY15: 18.3%) on the back of:
 - Growth and improved profitability in iihl and nib New Zealand.
 - First-time contribution of WNG.
- Robust Group underlying insurance margins
 - Group gross margin 18.6% (FY15: 16.4%).
 - Group net margin 7.1% (FY15: 5.6%).

¹ Other includes corporate expenses (share registry/directors fees) as well as investment in nib Options, offset by income from complementary products (life and related insurance commissions), travel insurance commissions prior to WNG acquisition (31 July 2015), as well as rent and licence fee income (Digital Health Ventures). Refer Slide 30 for breakdown of Other income & Expenses.

Percentages shown in graph are a percentage of Group UOP by business segment




Australian Residents Health Insurance (arhi)

Strong improvement in gross margin



	FY16	FY15	Change
Policyholder growth (%)	3.8	4.7	(0.9)%
Lapse (%)	12.6	12.3	0.3%
Premium revenue (\$m)	1,568.4	1,429.5	9.7%
Claims expense ¹ (\$m)	(1,334.1)	(1,238.9)	7.7%
Gross underwriting result (\$m)	234.2	190.6	22.9%
UOP (\$m)	94.5	71.9	31.4%



- UOP result of \$94.5m (▲31.4%) primarily due to:
 - Gross margin improvement of 160bps to 14.9%.
 - Risk equalisation contribution favourable to PCP (▲3.3%) reflecting success targeting over 55s.
 - Net policyholder growth almost 3x industry average of 1.3% with nib lapse steady.
- Qantas Assure performing to expectations (launched 31 March 2016).
- Rate of downgrading/upgrading remains broadly consistent with previous years.
- Increase in management expenses to \$140.1m (▲17.8%) due to increases in employee, acquisition costs and investment in new business (e.g. Qantas Assure).
- MER increased from 8.3% to 8.9%. MER excluding marketing (direct/indirect) costs was 5.9% (FY15: 5.8%).
 - Change in DAC amortisation period from 6 years to 5 years (from 1 April 2016) increased FY16 management expenses by \$1.8m.
- FY16 net margin 6.0% (FY15: 5.0%).

¹ Includes Risk Equalisation and State levies




International (Inbound) Health Insurance (iihi)

Gross margin and volume drives positive earnings performance



	FY16	FY15	Change
Policyholder growth (%)	28.0	58.5	(30.5)%
Premium revenue (\$m)	76.8	54.9	39.7%
Claims expense (\$m)	(41.7)	(29.4)	41.6%
Gross underwriting result (\$m)	35.1	25.5	37.5%
UOP (\$m)	17.2	12.2	41.2%



- Significant increase in revenue and earnings underpinned by ongoing growth and improved scale.
- Increase in claims expense (▲41.6%) a function of volume growth.
- International student business showing positive earnings trajectory following Saudi contract discontinued 1 March 2016.
- Management expenses up \$4.4m (▲32.2%) to support growth (marketing and employment costs).
- Margins viewed as sustainable.




nib New Zealand

Delivering against performance targets



	FY16	FY15	Change
Policyholder growth (%)	25.8 ¹	5.9	19.9%
Premium revenue (\$m)	173.6	150.4	15.4%
Claims (medical and PPB ² settlement) (\$m)	(121.0)	(96.8)	25.1%
Gross underwriting result (\$m)	68.3	51.7	32.0%
UOP (\$m)	17.3	8.7	99.9%



- UOP up almost 100% due to continued policyholder growth, success of PPB² settlement campaign, lower than forecast claims and OnePath acquisition (7 month result).
- Investment in growth continues to deliver results with approximately 45% of new sales through DTC channel.
- Successful transition of OnePath business. Positive feedback to date from advisors and no material shock lapse.
- Strong acceptance of PPB settlement offer campaign having positive impact on UOP. Refer slide 29 for further detail on PPB and settlement offer.
- Trajectory of returns has NZ business on track to deliver on return objectives.

¹ Includes policyholders from acquisition of OnePath Life NZ medical insurance business completed 1 December 2015. Excluding OnePath Life NZ, net policyholder growth for FY16 was 4.1%.

² PPB – Premium Payback product. Refer slide 29 for details of movement in PPB.



World Nomads Group (WNG)

Operating results in line with expectations




(\$m)	FY16 ¹
Gross Written Premium ²	112.2
Operating income	50.0
Operating expenses	(40.3)
UOP	9.7

- GWP up 5.6% due to strong international sales (sales in USA up more than 30% and UK more than 25% on FY15), offset by weak Australian market performance.
- Successful transition of business to nib ownership with minimal disruption.
- Growth plans being accelerated and supported to target international expansion and new business opportunities, with level of investment to impact FY17 UOP result.


WNG Sales

(Policies)



WNG GWP²

(\$m)



¹ FY16 is a 11 month result with WNG business acquired on 31 July 2015

² WNG is a distributor of travel insurance and earns a commission for policies sold, however GWP is shown as it is a key performance metric of the business, noting GWP excludes other sources of income such as Emergency Travel Assistance and Managing General Agent fees

³ WNG was acquired and was only consolidated in the nib results from 31 July 2015 (FY16), the numbers shown are a 12 month result



Investments, Gearing & Capital

Strong and efficient balance sheet




(\$m)	FY16	FY15	Change
Net investment income	16.9	31.4	(46.2)%
Finance costs	(5.2)	(3.4)	53.1%
Available capital above internal targets ¹	6.8	10.2	(33.3)%

¹ Allowing for payment of final dividend


Investments

- Profit on sale of PSG shares (\$m)
- Net investment income (\$m)
- Net percentage return (%)
- Normalised annualised investment return (%)



Gearing

- Finance Costs (\$m)
- Gearing ratio
- Maximum gearing ratio




² Net investment income in FY15 benefited \$5.4m from of sale of shareholding in PSG

- Group target capital and gearing remain in line with stated internal policies.
- Continued focus on maintaining an efficient balance sheet.
- Net investment income (▼46.2%) a combination of one off FY15 gain from sale of shareholding in PSG and equity market performance.
- Consolidated portfolio (85%/15%, Defensive/Growth) performed in line with market benchmarks.
- Finance costs (▲53.1%) due to increased debt funding associated with WNG acquisition (31 July 2015).
- Interest cover of 27:1 at 30 June 2016 well above debt covenant.
- APRA have published prudential policy outlook currently indicating a review of capital standards is envisaged in 2018/2019.



Dividends

Dividend reflects ongoing earnings growth



- FY16 final dividend increased to 9.0cps, fully franked (FY15: 6.0 cps)
 - Ex-dividend date – 8 September 2016
 - Record date – 9 September 2016
 - Payment date – 7 October 2016
- Full year dividend 14.75cps, fully franked (▲28.3%), represents full year payout ratio of 70% of NPAT.
- Dividend policy to continue to reflect payment of fully franked dividends at a payout ratio of 60% - 70% of full year NPAT.

A group of people are running on a beach at sunset, splashing water. The scene is captured in a warm, golden light, with the sun low on the horizon. The people are silhouetted against the bright background, and their movement is captured with a slight blur, emphasizing the dynamic nature of the scene. The water is splashing around them, creating a sense of energy and movement.

Mark Fitzgibbon

CEO & MANAGING DIRECTOR

FULL YEAR RESULTS 2016

nib



Regulatory reform

Expect PHI reforms and potential regulatory changes to be a net positive



- Market pricing for prostheses/medical devices.
- Improved transparency to assist consumers choose/compare health insurance products.
- Premium pricing deregulation.
- Potential reform to risk equalisation.
- Lifetime discounts.
- Second tier hospital default benefits.
- Public hospital cost shifting.
- Healthcare homes an opportunity for better coordination and management.

Ley targets \$800m medical devices waste

Health

Tim Binsted

Health Minister Susan Ley has pledged to review claims of exorbitant medical device prices, with up to \$800 million a year wasted, to halt sur-

places on our members," Medibank managing director George Savvides said. "The current system benefits manufacturers and private hospitals at the expense of patients."

Medibank said prices for identical products could be 45 per cent lower in the public system.

The insurer said prices in France

In response, NIB managing director Mack Fitzgibbon said Ms Ley had to tackle cost pressures driving up the cost of care and premiums. Mr Fitzgibbon said on Friday this "is a welcome and timely move by the minister".

"Consumers stand to benefit by as much as \$800 million a year and there'll be no impact upon the high quality of care we provide," he said.

Bupa, nib, Medibank Private back Ley's Medicare review

Healthcare

Tim Binsted

The nation's top health funds have dismissed the doctors' lobby's objections to a review of Medicare, saying the healthcare system is plagued by ineffective and unnecessary medical procedures and desperately needs reform.

Federal Health Minister Susan Ley on Sunday launched the consultation process for the Medicare

ibank, Bupa and nib, rallied to support the under-fire minister.

Bupa private health insurance managing director Dr Dwayne Crombie said there is "a tremendous amount of waste" in the health system.

"If we look at the public health evidence, there is an argument for screening the bowel, for breast screening and cardiovascular screening. There is virtually no

The MBS lists out-of-hospital services such as GP consultations, diagnostic and therapeutic services that are subsidised under the Medicare system.

The MBS review, launched in April, will assess the 5769 items listed on the schedule. Approximately 70 per cent of those items have not been changed since their introduction in 1984.

"The only way to ensure Australia can afford and sustain a high-



FY17 Outlook

Increased investment to support business expansion and earnings growth



Soft market conditions likely to continue into FY17 however nib expected to deliver volume growth within 4% - 5% target range.

Difficult to predict arhi claims inflation trajectory. Drawing rate inflation (per person) expected to be within range of 3% - 4% (FY16: 2.9%).

Focus on achieving net margin (arhi) within target range of 5.0% - 5.5% noting competitive pressures.

Change in arhi DAC amortisation period related to sales from past periods will add \$4.6m to FY17 acquisition expenses.

Adjacent businesses will continue to grow with NZ to increase earnings and improvement in international (inbound) business.

Investment in growth and expansion of WNG will result in a subdued FY17 UOP for that business.

Ongoing pursuit of new business opportunities and innovation to create enterprise value.



FY17 Guidance



- Consolidated UOP¹ of \$130m – \$140m (Statutory operating profit of \$122m – \$132m).
- Investment returns to be in line with relevant internal benchmarks².

¹ Refer slide 27 for breakdown of FY17 forecast one-off transaction/M&A costs and amortisation of acquired intangibles

² Internal Investment benchmarks

– Australian Regulatory capital (79%/21% defensive/growth) – target for portfolio bank bill index plus 1%

– New Zealand regulatory capital (100% defensive) (1) For core portfolio target is a 6 month bank bill index (2) For premium payback portfolio target is a 3.0 years interest rate swap index

– Surplus capital (100% defensive) – bank bill index

Questions & Answers



FULL YEAR RESULTS 2016



Appendix



FULL YEAR RESULTS 2016

nib



nib Policyholder & Other Data (underwriting segments)

nib Group	FY16	FY15
Total policyholders	726,710	665,458
– Australian Residents Health Insurance	529,398	509,897
– International (Inbound) Health Insurance	91,918	71,783
– nib New Zealand	105,394	83,778
nib New Zealand (Persons covered)	212,497	162,351
Employees (FTEs)	1,043¹	843
arhi		
Net policyholder growth	3.8%	4.7%
Market share	8.1%	7.9%
Persons covered	1,030,220	1,001,368
Average age of hospital persons covered (yrs)	38.8	37.9
Total policyholders “under 40”	208,966	210,398
– Growth in “under 40” segment	(0.7)%	(2.6)%
Total policyholders “over 55”	171,023	154,561
– Growth in “over 55” segment	10.7%	16.8%
Total hospital persons “20-39”	257,670	263,820
– Growth in hospital persons “20-39”	(2.3)%	(3.0)%
– Market share	9.5%	9.7%
Total hospital persons “55+”	225,625	205,119
– Growth in hospital persons “55+”	10.0%	18.0%
– Market share	6.5%	6.0%
arhi Sales by Channel (%)		
Direct (nib)	59.5%	58.4%
Broker	40.5%	41.6%

¹ FTEs include WNG employees



Detailed Income Statement (UOP)



(\$m)	FY16	FY15	Change
Net premium revenue¹	1,818.7	1,634.9	11.2%
- arhi	1,568.4	1,429.5	9.7%
- iihl	76.8	54.9	39.7%
- nibnz	173.6	150.4	15.4%
Net claims expense¹	(1,288.0)	(1,151.4)	11.9%
- Hospital claims paid (arhi)	(782.3)	(695.9)	12.4%
- Ancillary claims paid (arhi)	(333.4)	(328.5)	1.5%
- OSC provision movement (arhi)	(9.6)	(0.8)	1160.0%
- arhi claims incurred	(1,125.3)	(1,025.2)	9.8%
- iihl claims incurred	(41.7)	(29.4)	41.6%
- nibnz claims incurred	(121.0)	(96.8)	25.1%
Risk equalisation levy	(179.4)	(185.5)	(3.3)%
- OSC risk equalisation margin	(2.0)	0.8	(333.1)%
- Gross deficit	318.0	267.0	19.1%
- Calculated deficit	(495.5)	(453.3)	9.3%
State levies	(29.4)	(28.2)	4.1%
Decrease/(Increase) in premium payback liability	15.8	(1.9)	(929.5)%
Net claims incurred (excluding claims handling)	(1,481.1)	(1,367.1)	8.3%
Gross underwriting result	337.6	267.8	26.1%
- arhi	234.2	190.6	22.9%
- iihl	35.1	25.5	37.5%
- nibnz	68.3	51.7	32.0%
Underwriting expenses (including claims handling)	(209.2)	(175.6)	19.1%
- arhi	(140.1)	(118.9)	17.8%
- iihl	(18.1)	(13.7)	32.2%
- nibnz	(51.0)	(43.1)	18.4%
Net underwriting result	128.4	92.2	39.3%
- arhi	94.1	71.7	31.3%
- iihl	17.0	11.8	43.7%
- nibnz	17.3	8.7	99.9%
Other income	54.4	4.4	1141.1%
- WNG	50.0	-	NA
- nib Options	0.0	(0.1)	145.6%
- Other	4.4	4.4	(0.0)
Other expenses	(50.8)	(8.5)	496.2%
- WNG	(40.3)	-	NA
- nib Options	(2.6)	(3.0)	(13.6)%
- Other	(8.0)	(5.6)	43.6%
UOP	132.0	88.0	49.9%

¹ Net of reinsurance



Underlying to statutory operating profit

(\$m)	FY17 Guidance	FY16	FY15	Change
UOP	130 – 140	132.0	88.0	49.9%
- arhi	-	94.5	71.9	31.4%
- iihl	-	17.2	12.2	41.2%
- nibnz	-	17.3	8.7	99.9%
- WNG	-	9.7	-	NA
- nib Options	-	(2.5)	(3.0)	16.1%
- Unallocated	-	(4.2)	(1.7)	146.6%
Amortisation of acquired intangibles	(7.9)	(7.8)	(3.5)	121.6%
- arhi	-	-	-	-
- lihl	(0.8)	(0.9)	(0.3)	239.5%
- nibnz	(4.0)	(3.4)	(3.3)	2.9%
- WNG	(3.1)	(3.6)	-	NA
One-off transaction and M&A costs	-	(3.4)	(2.8)	19.0%
- arhi	-	-	-	-
- iihl	-	-	-	-
- nibnz	-	-	-	-
- WNG	-	(1.9)	-	NA
- nib Options	-	-	(0.8)	NA
- Unallocated	-	(1.5)	(2.1)	(29.9)%
Statutory Operating Profit	122 – 132	120.8	81.7	47.9%



Detailed Management Expenses (Underwriting segments)



(\$m)	Employment	Marketing	Marketing Indirect Commissions (Paid)	Marketing Indirect Commissions (deferred)	Marketing Indirect Commissions (Amortised)	IT	Occupancy	Other	Total Underwriting Expenses	MER% Underlying Expenses	Amortisation of acquired intangibles	Total Management Expenses	MER %
Australian Residents Health Insurance													
FY14	49.8	20.4	17.6	(16.0)	5.4	9.3	5.9	13.9	106.4	8.1%	-	106.4	8.1%
FY15	53.0	25.8	32.1	(30.2)	8.4	9.9	5.9	14.1	118.9	8.3%	-	118.9	8.3%
FY16	57.6	29.8	30.9	(29.0)	15.7	10.7	6.1	18.2	140.1	8.9%	-	140.1	8.9%
International (Inbound) Health Insurance													
FY14	5.4	1.3	1.5	(1.4)	0.4	1.2	0.6	0.8	9.9	25.9%	0.2	10.1	26.6%
FY15	8.1	1.2	2.4	(2.3)	1.6	1.3	0.6	0.9	13.7	24.9%	0.3	13.9	25.3%
FY16	10.0	1.1	3.8	(3.4)	2.6	1.7	0.7	1.5	18.1	23.5%	0.9	18.9	24.7%
nib New Zealand													
FY14	12.1	5.7	18.1	(9.7)	9.3	2.3	0.8	3.0	41.6	29.9%	4.0	45.6	32.8%
FY15	12.5	4.8	20.3	(11.6)	9.6	2.9	1.2	3.3	43.1	28.6%	3.3	46.3	30.8%
FY16	14.0	5.5	25.6	(15.0)	10.9	3.1	1.3	5.7	51.0	29.4%	3.4	54.3	31.3%



Premium Payback (PPB)

Reduction in PPB liability having positive impact on UOP



Movement in central estimate of PPB liability

(\$m)	FY16	FY15
Opening Balance – central estimate	38.0	36.8
Funding – new premium less medical claims (discounted)	5.0	7.4
Payouts (normal)	(6.9)	(8.2)
Payouts (early settlement)	(13.9)	-
Release of reserves on early settlements	(1.7)	-
Movement in discount rate	2.0	2.0
Discount rate – duration impact	1.0	1.6
Effect of changes in foreign exchange rates	2.0	(1.6)
Closing Balance – Central estimate	25.6	38.0

- Premium Payback (PPB) relates to previously offered products, where customers are entitled to receive a refund (or partial refund) of premiums paid less any claims made, once the policy has been in force for a specified period.
- A PPB liability is recognised for these products. It is determined based on the discounted value of accumulated excess of premiums over claims at an individual policy level.
- The PPB liability is matched with investments of approximately the same duration.
- Campaign currently underway to shift customers off PPB product.

nib New Zealand UOP split between PPB and non PPB

(\$m)	Non PPB	FY16 PPB	Total	Non PPB	FY15 PPB	Total
Premium revenue	161.6	12.0	173.6	135.3	15.1	150.4
Claims (medical)	(96.5)	(3.7)	(100.2)	(83.7)	(4.9)	(88.6)
Premium payback liability settlement ¹	-	(20.8)	(20.8)		(8.2)	(8.2)
Decrease/(Increase) in premium payback liability ²	-	15.8	15.8		(1.9)	(1.9)
Gross underwriting result³	65.1	3.2	68.3	51.7	0.1	51.7
Management expenses			(51.0)			(43.1)
UOP			17.3			8.7

¹Premium payback liability settlement includes \$13.9m relating to the early settlement campaign

²Decrease in premium payback liability includes \$16.0m relating to early settlement campaign

³Gross underwriting result includes \$2.1m relating to early settlement campaign



Other Income & Expenses



(\$m)	FY16	FY15	Change
Other income			
Complementary insurance	2.3	2.4	(5.6)%
nib Options income	0.0	(0.1)	145.7%
Agency fee (exc nib Options)	0.3	0.3	0.3%
Rental income	0.7	1.0	(21.5)%
Digital Health Ventures income	0.2	0.5	(52.2)%
Other	0.2	(0.3)	153.4%
Total Other Income	3.8¹	3.8	0.0%
Other expenses			
Complementary insurance expenditure	(0.7)	(0.2)	297.8%
nib Options expenditure	(2.6)	(3.0)	(13.6)%
Share registry and other corporate overheads	(4.6)	(4.3)	5.8%
Digital Health Ventures expenditure	(2.4)	(0.9)	158.7%
Other	(0.4)	(0.3)	18.3%
Total other expenses	(10.5)	(8.5)	23.6%

¹ Excludes non-recurring profit from sale of Newcastle office building



Investment Asset Allocation



	Consolidated		Australian Investment Portfolio		New Zealand Investment Portfolio	
	Balance (\$m) at 30/06/2016	Allocation (%) at 30/06/2016	Net return (\$m) 12 months to 30/06/2016	Allocation (%) at 30/06/2016	Net return (\$m) 12 months to 30/06/2016	Allocation (%) at 30/06/2016
Cash ¹	120.2	18.8%	3.6	19.7%	0.5	13.2%
Fixed Interest	422.7	66.0%	8.4	62.4%	3.8	86.8%
Total defensive	542.9	84.7%	12.0	82.1%	4.3	100.0%
Australian Shares	36.0	5.6%	0.1	6.6%	-	-
Global shares – hedged	10.3	1.6%	(0.0)	1.9%	-	-
Global shares – unhedged	35.7	5.6%	(0.5)	6.5%	-	-
Global property	15.9	2.5%	0.9	2.9%	-	-
Property trusts	0.0	0.0%	0.1	0.0%	-	-
Total growth	97.8	15.3%	0.6	17.9%	0.0	0.0%
Total	640.8	100.0%	12.6	100.0%	4.3	100.0%

¹ Excludes operating cash of \$29.4m, noting total cash is split between cash and cash equivalents of \$89.4m and short term deposits of \$60.2m included in Financial Assets at Fair Value Through Profit or Loss.

² Sale of Newcastle office building for \$46.6m (15 year lease, plus 2 x 5 year options) with settlement occurring 29 February 2016.